Oruka Therapeutics Overview
Oruka Therapeutics Target Price
Analysts' 12-month price predictions for ORKA.
Get informed when a big investor buys or sells
+ FollowShare Price
$57.2
Average Target Price
$130.44
128% upside
128% upside9 analysts in the last 4 months
High: $200 | Low: $73
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-04-30 | Leerink Partners | $120 | 109.8% upside |  |
| 2026-04-29 | H.C. Wainwright | $120 | 109.8% upside | |
| 2026-04-28 | UBS | $100 | 74.8% upside | |
| 2026-04-27 | Wedbush | $165 | 188.5% upside | |
| 2026-04-27 | BarclaysEtzer Darout | $160 | 179.7% upside | |
| 2026-04-27 | Guggenheim | $200 | 249.7% upside | |
| 2026-04-27 | BTIG | $151 | 164% upside | |
| 2026-04-15 | Wedbush | $85 | 48.6% upside | |
| 2026-03-13 | BTIGJulian Harrison | $73 | 27.6% upside | |
| 2026-01-13 | Wedbush | $45 |  21.3% downside | |
| 2026-01-07 | UBSMichael Yee | $50 | 12.6% downside | |
| 2025-12-18 | Piper Sandler | $75 | 31.1% upside | |
| 2025-10-27 | Guggenheim | $60 | 4.9% upside | |
| 2025-10-27 | H.C. WainwrightMitchell Kapoor | $40 | 30.1% downside | |
| 2025-10-13 | Barclays | $48 | 16.1% downside | |
| 2025-02-04 | Wolfe ResearchAndy Chen | $20 | 65% downside | |
| 2024-09-12 | JefferiesMichael Yee | $40 | 30.1% downside | |
| 2024-09-04 | WedbushDavid Nierengarten | $40 | 30.1% downside | |